When these foam cells die and are not cleared from the subendothelium, they contribute to necrotic core formation, which can lead to plaque rupture and thrombosis. 1 Macrophages expressing anti-inflammatory cytokines promote anti-inflammatory signaling to reduce the inflammatory environment of the plaque and contribute to plaque regression by participating in efferocytosis, the clearance of dying cells. 8 Furthermore, efferocytosis enhances anti-inflammatory signaling and cholesterol efflux within the phagocytic macrophage preventing it from turning into a proinflammatory foam cell. 9, 10 Thus, tipping the balance of macrophage phenotype to an anti-inflammatory phenotype presents a significant therapeutic potential.
Epsins are a family of evolutionarily conserved, multidomain containing proteins involved in clathrin-mediated endocytosis. [11] [12] [13] [14] [15] Epsins 1 and 2 are ubiquitously expressed, whereas epsin 3 is expressed primarily in the stomach. Mice lacking either epsins 1 or 2 develop normally and exhibit no apparent phenotype suggesting that both are redundant in function. 11, 12, 16 Mice constitutively lacking epsins 1 and 2 are embryonic lethal because of vascular defects suggesting that epsins are required for normal development of the vasculature. However, mice with a global inducible knockout of epsins 1 and 2 develop normally. 12, 16 We have previously shown that mice with an inducible endothelial cell-specific deletion of epsins 1 and 2 exhibit impaired tumor growth because of aberrant tumor angiogenesis demonstrating a role for epsins in the regulation of the vasculature. 11, 12 Furthermore, recent genome-wide association studies have identified several genes involved in cancer that are associated with cardiovascular disease suggesting a possible involvement for epsins in cardiovascular disease. 17, 18 In addition, it has been reported that epsin 1 binds to LDLR (LDL receptor) in a ubiquitindependent manner. 19 Although other reports, as well as our data, suggest this is not the case, 20 it suggests the possibility that epsins bind to proteins essential in the development of atherosclerosis.
LRP-1 (LDLR-related protein 1) is a multifunctional and ubiquitously expressed member of the LDLR family consisting of a 515 kDa extracellular chain noncovalently linked to an 85 kDa chain with transmembrane and cytoplasmic regions. 21, 22 The extracellular chain consists of 4 ligand binding domains that bind to over 40 different ligands. 22 Global knockout of LRP-1 is embryonic lethal, 23 but a myeloid-specific deletion of LRP-1 in atherosclerotic mouse models has been shown to exhibit increased atherosclerosis with macrophages that exhibit increased foam cell formation, increased expression of proinflammatory markers, and decreased efferocytosis of apoptotic cells. 24, 25 Macrophage LRP-1 is also known to mediate efferocytosis, the phagocytosis of dying cells, by binding to receptors on the dying cell thereby mediating their phagocytosis. 24, 26, 27 Furthermore, the process of efferocytosis has been demonstrated to promote an anti-inflammatory macrophage phenotype. 9 
Novelty and Significance
What Is Known?
• Macrophages are a major contributing cell type in inflammation and atherosclerosis.
• Epsins play a role in the endocytosis and degradation of select proteins thereby regulating angiogenesis.
• LRP-1 (low-density lipoprotein receptor-related protein 1) in macrophages promotes anti-inflammatory signaling and efferocytosis while inhibiting the progression of atherosclerosis.
What New Information Does This Article Contribute?
• Using a new mouse model in which epsins are selectively deleted from myeloid cells, we show that epsins promote inflammatory macrophage phenotype and the development and progression of atherosclerosis.
• Epsins deficiency in myeloid cells resulted in decreased plaque burden, increased plaque stability, and macrophages exhibiting reduced inflammation and lipid content and increased efferocytosis. • In the presence of proinflammatory stimuli, epsins bind to ubiquitinated LRP-1 removing LRP-1 from the surface of macrophages and thereby promoting inflammation and atherosclerosis.
Macrophages play an essential role in inflammatory processes that promote atherosclerosis. We deleted epsins from myeloid cells, including macrophages, in a mouse model of atherosclerosis and found a decrease in lesional macrophage content and overall plaque progression. Epsins deletion shifted macrophage phenotype from proinflammatory to anti-inflammatory. Mechanistically, proinflammatory stimuli cause increased binding between LRP-1 and epsins resulting in the internalization of LRP-1 from the cell surface and its potential degradation.
this protein has also been shown to undergo ubiquitination and endocytosis. [28] [29] [30] [31] Thus, deciphering the mechanisms that regulate LRP-1 expression in macrophages is an important step in developing new therapies for the treatment of atherosclerosis.
In this study, we investigate the potential role epsins play in regulating atherosclerosis using a unique mouse model with a myeloid cell-specific epsins double knockout (LysM-DKO). We discover that epsins are upregulated in macrophages of atherosclerotic mice. Furthermore, myeloid-specific epsins deficiency ameliorates the development of atherosclerosis and shifts macrophage phenotype to an anti-inflammatory phenotype while enhancing efferocytosis. Mechanistically, we found that epsins interact with ubiquitinated LRP-1. Without epsins, surface levels of LRP-1 are abundant in macrophages possibly resulting in enhanced efferocytosis and anti-inflammatory macrophage phenotype but reduced foam cell formation and ultimately reduced atherosclerosis. Genetically reducing the levels of LRP-1 in LysM-DKO mice, in part, restores the proinflammatory phenotype exhibited by wild-type (WT) mouse macrophages. Thus, we propose a model in which epsins' upregulation in atherosclerosis promotes LRP-1 downregulation thereby enhancing the development of atherosclerosis.
Methods
The authors declare that all supporting data are available within the article and in the Online Data Supplement. Complete methods are available in the Online Data Supplement.
Results

Epsins Are Augmented in Atherosclerosis
We have previously established that epsins play an important role in angiogenesis and tumor angiogenesis. 11, 12, 32, 33 Recent genome-wide association studies have identified several genes for cancer that are also associated with coronary artery disease 17, 18 ; thus, we hypothesized that epsins may play a critical role in atherosclerosis. Immunofluorescent staining for epsin 1 and CD68 (macrophage) in normal human aorta samples and atherosclerotic patient aorta samples demonstrated increased staining of both epsin 1 and CD68, as well as increased costaining of epsin 1 and CD68, in atherosclerotic lesion samples compared with normal aorta samples (Online Figure I) suggesting that epsins are upregulated in human atherosclerotic lesions particularly in macrophagerich regions. Additionally, aortic root sections from ApoE −/− mice fed normal diet and Western diet (WD) were stained for epsin 1 and F4/80 (macrophage). The intensity of the epsin 1 staining in the F4/80 positive region of the plaque in mice fed WD was significantly greater than that of mice fed normal diet and increased with increased time on WD ( Figure 1A ). This suggests that epsin 1 expression is significantly increased in the macrophage-rich region of lesions as atherosclerosis progresses. Furthermore, elicited peritoneal macrophages were isolated from ApoE −/− mice on normal diet and WD. We found that the protein and mRNA expression of both epsin 1 and epsin 2 was upregulated in macrophages from mice fed WD ( Figure 1B and 1C ) again suggesting that epsins expression is significantly increased in macrophages in atherosclerosis.
Generation of Myeloid-Specific Deletion of Epsins 1 and 2 Mice
Given the importance of macrophages in the development and progression of atherosclerosis and our findings, we hypothesized that macrophage epsins play a crucial role in atherosclerosis. Thus, we generated a novel mouse model selectively, but constitutively, lacking epsin 1 in myeloid cells on an epsin 2 null background. We achieved this by crossing Epn1 fl/fl ;Epn2 −/− mice 11, 16 with mice expressing a single copy of LysM Cre. 34 These mice were backcrossed onto the C57BL/6 background to generate Epn1 fl/fl ;Epn2 −/− ;LysM Cre +/− (LysM-DKO) mice. Because epsins 1 and 2 are redundant in function, both epsins 1 and 2 were deleted. However, because double knock out of epsins 1 and 2 is embryonic lethal, only epsin 2 was deleted globally, whereas epsin 1 was deleted selectively in myeloid cells using the cre lox system. Deletion of epsins 1 and 2 was validated in elicited peritoneal and bone marrow-derived macrophages by Western blotting (Online Figure II) . 11, 16, 34 To evaluate the role of myeloid epsins in the development of atherosclerosis, these mice were further crossed to 
Myeloid-Specific Deletion of Epsins Ameliorates Atherosclerosis
We analyzed the development and progression of atherosclerosis in the ApoE −/− and ApoE −/− /LysM-DKO mice fed WD. No change in plasma glucose, cholesterol levels, or triglyceride levels was observed in ApoE −/− and ApoE −/− /LysM-DKO mice fed WD for 14 to 16 weeks (Online Table III) . Additionally, no change in circulating myeloid cells or immune and inflammatory cell populations in blood and bone marrow were observed (Online Table IV Figure VI) . Furthermore, loss of myeloid epsins resulted in a decrease in macrophage content within the atheroma as evidenced by reduced CD68 staining in aortic root sections ( Figure 1E ). Collectively, this data demonstrates that loss of myeloid epsins ameliorates the development and progression of atherosclerosis. 
Myeloid-Specific Deletion of Epsins Enhances Atheroma Stability
The reduction in CD68 staining in ApoE −/− /LysM-DKO aortic root sections not only suggests that these atheromas contain fewer macrophages but also that these atheromas are more stable compared with ApoE −/− atheromas ( Figure 1E ). Hallmarks of a stable atheroma include reduced recruitment of immune and inflammatory cells, increased smooth muscle cell content within the cap area of the atheroma, as well as decreased apoptosis and necrosis within the atheroma. 8, 35, 36 To analyze atheroma stability in vivo, we analyzed the composition of immune and inflammatory cells in the aortas of both ApoE −/− and ApoE /LysM-DKO mice suggesting that there may be no phenotypic difference in this cell type. Furthermore, these cells constitute a much smaller portion of the cells within the aorta. We also found increased smooth muscle cell content within the cap area of the atheroma via immunofluorescent staining of aortic root sections as well as decreased necrotic core area within the atheroma via H&E staining in aortic root sections in the ApoE −/− / LysM-DKO mice compared with ApoE −/− mice ( Figure 2B  and 2C ). This further suggests that myeloid-specific epsins deficiency enables atheroma stability.
Myeloid-Specific Deletion of Epsins Reduces Foam Cell Formation in Primary Macrophages by Inducing Macrophage Efferocytosis and an AntiInflammatory Macrophage Phenotype
To analyze the effect epsins deficiency had specifically on macrophages from these mice, we isolated primary macrophages from ApoE −/− and ApoE −/− /LysM-DKO mice on WD. Epsins deficiency resulted in a significant reduction in foam cell formation as demonstrated with Oil Red O staining of bone marrow-derived macrophages treated with ox-LDL ( Figure 3A) . This was confirmed in elicited peritoneal macrophages from these mice as shown by a significant reduction in cells double positive for F4/80 and Bodipy 37 ( Figure 3B ). We further confirmed the beneficial phenotype of ameliorated atherosclerosis and reduced foam cell formation in epsins deficient macrophages using primary macrophages from WT and LysM-DKO mice injected with PCSK9 (proprotein convertase subtilisin/ kexin type 9)-AAV, which reduces LDLR levels in the liver and increases lipid levels in the mouse and fed WD (Online Figure  VIII) . 38 These mice also exhibited no change in cholesterol levels or circulating immune cells (Online Figure IX) .
Efferocytosis, the clearance of dead and dying cells by phagocytes, functions to remove dead cells from the plaque thereby preventing secondary necrosis and release of cytotoxic and inflammatory contents from dying cells. 8 To analyze the role of epsins deficiency on efferocytosis in vitro, green-labeled apoptotic WT thymocytes were cocultured with red-labeled primary elicited peritoneal macrophages from WT and LysM-DKO mice. In epsins deficient macrophages, with or without an ApoE −/− background, the percentage of efferocytosis was dramatically increased compared with WT macrophages ( Figure 3C ). To analyze efferocytosis in vivo, green-labeled apoptotic WT thymocytes were injected into WT and LysM-DKO mice 2 hours before harvesting elicited peritoneal macrophages and analyzed via flow cytometry. Again, with or without the ApoE −/− background, epsins deficient macrophages exhibited a significant increase in efferocytosis compared with WT macrophages (Online Figure XA) .
Several studies have shown that macrophage efferocytosis stimulates signaling pathways within the phagocyte resulting in increased production and release of anti-inflammatory signals, as well as the induction of anti-inflammatory macrophage phenotype. Epsins deficiency reduced foam cell formation and the proinflammatory macrophage phenotype while enhancing the anti-inflammatory macrophage phenotype and efferocytosis in primary macrophages. These characteristics are indicators of stable atheromas that are unlikely to rupture. 8, 35, 36 Thus, these findings further suggest that atheromas of myeloid-specific epsins deficient mice may be more stable than those of ApoE −/− mice.
Myeloid-Specific Epsins Deficiency Augments Total and Surface Protein Levels of LRP-1
Interestingly, atherosclerotic mice with myeloid-specific deletion of LRP-1 have been shown to have a phenotype that is the opposite of the ApoE −/− /LysM-DKO phenotype. 24, 26, 27 Given the negative correlation between atherosclerotic phenotypes of myeloid-specific deletion of LRP-1 and myeloid-specific deletion of epsins mice and epsins' function as endocytic adaptors for ubiquitinated plasma membrane proteins, [11] [12] [13] [14] [15] 24 we hypothesized that the phenotype of our myeloid-specific epsins deletion mice is because of increased LRP-1 surface and total protein levels in macrophages because of the absence of epsins-mediated downregulation of LRP-1. We analyzed protein levels of several surface receptors on macrophages that are involved in the development of atherosclerosis. Specifically, we observed LRP-1 staining with greater intensity in aortic root sections from ApoE Figure XIA) . LRP-1 is known to have antiatherosclerotic and anti-inflammatory functions, and its deletion from macrophages results in a dramatic increase in lesion size in ApoE −/− mice. 24 Furthermore, this protein has been shown to undergo both ubiquitination and endocytosis. 30, 31 Thus, epsins may bind to ubiquitinated LRP-1 under inflammatory conditions resulting in the removal of LRP-1 from the macrophage cell surface and thereby reducing efferocytosis and promoting inflammation and the development of atherosclerosis. In fact, Figure XIC) . Thus, when macrophages lack epsins, total LRP-1 levels increase, and LRP-1 accumulates on the surface of the macrophages.
Deficiency of Epsins Reduces LRP-1 Internalization
To determine if epsins interact with ubiquitinated LRP-1 to enable the internalization of LRP-1, we analyzed cell surface and internalized levels of LRP-1 in the presence and absence ) mouse (WT) thymocytes and labeled with CMTPX (red). Percent efferocytosis was quantified as the number of Mɸs with engulfed apoptotic cells as a percentage of total Mɸs. Scale bar=20 μM. D, RNA was isolated from BMDMɸs (n=5), cDNA was made, and quantitative polymerase chain reaction was performed using primer pairs for the indicated genes. *ApoE −/− /LysM-DKO group vs ApoE −/− group, P<0.01; #LysM-DKO group vs WT group, P<0.01. Arg1 indicates arginase 1; IL, interleukin; iNOS, inducible nitric oxide synthase; MCP, monocyte chemoattractant protein 1; and TNF, tumor necrosis factor. e13 of epsins. Primary macrophages from WT and LysM-DKO mice in culture were biotinylated followed by treatment or no treatment with ox-LDL to induce the internalization of LRP-1. Biotin was cleaved to determine internalized LRP-1 levels only and pulled down using Neutravidin beads. WT macrophages exhibited internalization of LRP-1 at 5, 10, ) mouse (WT; n=5) and LysM-DKO mice (n=5) were lysed for Western blot (WB). C, Elicited peritoneal Mɸs from WT (n=3) and LysM-DKO (n=3) mice were biotinylated and processed for neutravidin beads pull down followed by WB. D, Elicited peritoneal Mɸs from WT (n=5) and LysM-DKO (n=5) mice were biotinylated, treated with or without ox-LDL (oxidized LDL; 10 μg/mL) for indicated time points, and treated with or without cleavage buffer followed by processing for neutravidin beads pull down and WB. E, WT and epsins 1 and 2 double knockout mouse (DKO) embryonic fibroblasts (MEFs) transfected with FLAG-tagged LRP1 were labeled with anti-FLAG antibodies. Cells were treated with ox-LDL (10 μg/mL) for the indicated time points followed by treatment with antibody stripping buffer and staining with secondary antibodies and DAPI. Images were taken at ×60. Scale bar=5 μm. ABCA indicates ATP-binding cassette transporter A1. 
Epsin Interacts With LRP-1 Via the Epsin UIM Domain
We next sought to determine how epsins and LRP-1 interact to cause this disparity in LRP-1 surface and total protein levels as well as internalization in macrophages from ApoE −/− and ApoE −/− /LysM-DKO mice. When WT bone marrow-derived macrophages and RAW264.7 cells are lysed and processed for immunoprecipitation with anti-epsin 1 antibodies, we saw coimmunoprecipitation of LRP-1 ( Figure 5A ) indicating that epsin 1 and LRP-1 interact endogenously. Furthermore, this interaction between epsin 1 and LRP-1 seems to be specific as epsin 1 does not interact with other cell surface receptors, such as LDLR, ABCA1 (ATP-binding cassette transporter A1), or CD36 in macrophages (Online Figure XIII) . Similar results are obtained with the reciprocal immunoprecipitation (data not shown).
To determine if the binding between epsin 1 and LRP-1 is ubiquitin-dependent, we analyzed the binding between LRP-1 and an epsin 1 construct lacking the ubiquitin-interacting motif. We used an LRP-1 construct containing a truncated extracellular domain, which has been shown to function and traffic identically to the full-length LRP-1 protein. 39, 40 We recapitulated the binding between full-length epsin 1 and LRP-1. However, binding between epsin 1 construct lacking the ubiquitin-interacting motif and LRP-1 was significantly reduced suggesting that epsin's UIM is essential for binding with LRP-1 ( Figure 5B) . Several studies have shown that LRP-1 is ubiquitinated in response to various stimuli. 30, 31 We found that LRP-1 is ubiquitinated in RAW264.7 cells in response to ox-LDL treatment in the presence of the proteasome inhibitor MG132 ( Figure 5C ). This suggests that, within the proinflammatory environment of the atheroma with abundant levels of ox-LDL, LRP-1 is ubiquitinated. Additionally, we created a ubiquitin deficient LRP-1 plasmid by mutating 3 lysine residues in the cytoplasmic tail to arginine (Online Figure XIV) . Furthermore, if we have increased ubiquitination of LRP-1 in response to a proinflammatory environment, then we should also see increased binding between LRP-1 and epsin 1 in this proinflammatory environment. We found that, on ox-LDL stimulation, the interaction between epsin 1 and LRP-1 is increased in primary WT macrophages ( Figure 5D ) suggesting that within the proinflammatory environment of the atheroma, LRP-1 is ubiquitinated, bound to epsin, and internalized.
Genetic Reduction of LRP-1 in MacrophageSpecific Epsins Deficient Mice Restores Atherosclerosis
To confirm that the phenotype of the ApoE −/− /LysM-DKO mice is at least partially a result of increased LRP-1 total and surface protein levels because of loss of epsins, we crossed these mice with LRP-1 fl/fl mice to create mice with myeloidspecific epsins deficiency and a myeloid-specific haploinsufficiency of LRP-1 (ApoE 
Discussion
Several studies have demonstrated the importance of epsins in endothelial cells in the regulation of the vasculature both physiologically and pathologically. 11, 12, 32, 33 However, the role of epsins in macrophages, a significant contributor to the progression of atherosclerosis, is unknown. This study revealed the critical role that epsins play in macrophages and their impact on the development and progression of atherosclerosis. Our findings demonstrate that epsins act in a proatherogenic fashion to downregulate receptors involved in reducing inflammation and plaque progression. Furthermore, we demonstrate a novel regulatory mechanism for LRP-1 in macrophages ( Figure 7) . We propose a model in which epsins bind ubiquitinated LRP-1 resulting in loss of LRP-1 from the cell surface leading to increased foam cell accumulation, decreased efferocytosis, increased inflammation, and further atheroma development. Thus, epsins are critical regulators of LRP-1 expression. However, what ubiquitin ligase ubiquitinates LRP-1 in this context is unknown, and this determination will require future studies involving immunoprecipitations or siRNA knockdowns. Recent work from our lab has demonstrated that the transcription factor AP-1 (activator protein-1) enhances epsins expression under diabetic conditions. 41 Interestingly, AP-1 deficiency has been shown to be atheroprotective in hyperlipidemic mice and has increased activation in progressive plaques. 42 Further studies will need to confirm if AP-1 enhances the transcription of epsins in macrophages in atherosclerotic conditions.
Although it has been reported that epsins interact with the actin cytoskeleton, the role of this interaction in the development and progression of atherosclerosis and the function of macrophages is less clear. 43 Given this connection between epsins and the actin cytoskeleton, we suspect that epsins deficiency may affect nonreceptor mediated lipid uptake, which predominates at levels of ox-LDL that exceed receptor saturation and relies heavily on the actin cytoskeleton. 44 In addition, recent studies have linked autophagy to the actin cytoskeleton and have demonstrated that autophagy is deficient under atherosclerotic conditions. 45 Thus, further studies are needed to determine what role epsins play in the regulation of autophagy and autophagic flux. Several studies have shown LRP-1 to be essential to efferocytosis, a process which clears dead cells and promotes plaque regression. 24, 26, 27 Importantly, we provide evidence that loss of myeloid epsins increases efferocytosis of apoptotic cells by macrophages in vitro and in vivo, demonstrating a critical role for macrophage epsins expression in efferocytosis, which may be mediated by its impact on LRP-1 expression. Interestingly, upregulation of LRP-1 with glucocorticoid treatment results in the upregulation of efferocytosis. 46 This supports a mechanism in which epsins deficiency promotes efferocytosis by upregulating LRP-1, whereas other proteins traffic LRP-1 to and from the cell surface and lysosomes during efferocytosis. Furthermore, LRP-1 downregulates cell surface expression of TNFR1 (tumor necrosis factor receptor 1), 25 which has been shown to upregulate inflammation and apoptosis. 47 Therefore, the increased expression of LRP-1 in epsins deficient macrophages is likely responsible for the anti-inflammatory phenotype of these macrophages. Future studies will be needed to determine any changes in total and surface protein levels of TNF 1 in WT and LysM-DKO macrophages to confirm that this anti-inflammatory effect of epsins deficiency does act through LRP-1's downregulation of TNF1. Decreased signaling of LRP-1 has been demonstrated to result in decreased ABCA1 expression via Akt induced PPARγ/LXR function. 48 Although we have not seen any significant changes to the ABCA1 expression levels in WT and LysM-DKO macrophages, additional studies will be needed to determine if there is any change in Akt signaling or cholesterol efflux in WT and LysM-DKO macrophages. Several publications have reported no phenotype for a cell type-specific haploinsufficient LRP-1 mice suggesting that the phenotype of these mice does not differ from that of control mice.
24,27 Thus, we suspect that the phenotype seen in ApoE −/− /LysM-DKO-LRP1 fl/+ mice is because of the reduced expression of LRP-1 in the LysM-DKO background rather than elimination of LRP-1.
We think the interaction between LRP-1 and epsins to be specific. We have found no interaction between epsins and ABCA1, LDLR, or CD36. However, it is possible that epsins bind other receptors on the macrophage surface that act to reduce inflammation and plaque progression, such as ABCG1, SR-BI (scavenger receptor class B type 1), or MerTK. The phenotypes of mouse models with a reduction in any of these 3 proteins, either globally or myeloid-specific, are not only similar to each other but also in opposition to that of the ApoE −/− /LysM-DKO mice. [49] [50] [51] [52] [53] Thus, epsins may act through multiple receptors in macrophages. Efferocytosis receptors may overlap in function; however, removing just 1 efferocytosis receptor from macrophages results in a significant decrease in efferocytosis and an increase in inflammation and atheroma development. If epsins interact with multiple receptors, targeting epsins may provide a more robust treatment option than simply targeting 1 protein because of potential effects through several parallel pathways. Future studies will need to address the ability of epsins to bind or regulate any of these other proteins that play such an integral role in the development and progression of atherosclerosis.
Many current therapies used to treat patients with cardiovascular disease focus on ameliorating hypertension and lowering lipid levels. However, these treatments yield less than ideal results. New treatments that address the high levels of inflammation and cell death and low levels of dead cell clearance may help to fill this gap. Targeting a molecule, such as epsins, would potentially reduce macrophage lipid uptake, reduce macrophage proinflammatory phenotype, and increase efferocytosis ultimately reducing the progression of and risk for atherosclerosis. Furthermore, if epsins interact with more efferocytosis receptors than just LRP-1, epsins may have a more profound effect in diminishing atherosclerosis by acting through multiple pathways. In addition, adverse side effects from blocking epsins in adults is predicted to be minimal considering that adult mice with an inducible global knock out of epsins 1 and 2 exhibit no apparent defects under normal conditions. 16 Previous studies have shown that using a UIM peptide effectively blocks the interaction between epsins and VEGFR2 (vascular endothelial growth factor receptor 2) reducing tumor growth and metastasis with minimal toxicity in a mouse cancer model. 32, 33 Thus, targeting this UIM peptide to macrophages holds significant promise as a potential therapeutic option in atherosclerosis. In conclusion, our findings demonstrate that epsins are critical regulators of inflammation and atherosclerosis and represent a potential novel therapeutic target for the development of treatments for atherosclerosis.
